CN104774325A

CN104774325A - Polymer FA-P85-PLA as well as preparation method and application thereof

Info

Publication number: CN104774325A
Application number: CN201510161889.6A
Authority: CN
Inventors: 熊向源; 罗月圆; 龚妍春; 李资玲; 李玉萍
Original assignee: Jiangxi Science and Technology Normal University
Current assignee: Jiangxi Science and Technology Normal University
Priority date: 2015-04-08
Filing date: 2015-04-08
Publication date: 2015-07-15
Anticipated expiration: 2035-04-08
Also published as: CN104774325B

Abstract

The invention relates to a polymer FA-P85-PLA as well as a preparation method and application thereof, belongs to the field of biomedicines and relates to an indicating drug carrier. The invention discloses a polymer, and the polymer combines the functions of the drug carrier and indication and can effectively find out whether the drug carrier enters cells or not and find out the quantity of the drug carrier entering the cells, thereby having good prospects. In addition, the drug carrier provided by the invention has good biocompatibility.

Description

A kind of polymkeric substance FA-P85-PLA and preparation method thereof and application

Technical field

The invention belongs to biomedicine field, relate to a kind of indicator type pharmaceutical carrier.

Background technology

We know, current most of medicine (as cancer therapy drug) is hydrophobic, namely water insoluble, is easy to be excreted by a series of rejections in human body, as medicine resistancing action, enzyme degradation etc., which greatly limits the validity of the disease treatments such as cancer.And the nanoparticle that biocompatibility amphipathy macromolecule is formed can as pharmaceutical carrier; pharmaceutical pack is embedded in hydrophobic core; surface is protected by the hydrophilic layer of nanoparticle, and such medicine just can be transported to diseased region (as tumour etc.), thus plays the effect of effective Therapeutic cancer.So-called amphipathy macromolecule, namely contains the macromolecular material of hydrophilic segment and hydrophobic segment.Wherein polylactide [poly (lactic acid), PLA] is the usually selected hydrophobic segment of a class, because it not only has biocompatibility but also have biodegradability, is also used by U.S. FDA approval.It can be degraded into small molecules in human body, thus is easy to be excreted, so it is widely used in biomedicine field.As pharmaceutical carrier, Pluronic segmented copolymer is also the polymkeric substance that a class is widely studied, Pluronic is one business-like product, have good biocompatibility, the Pluronic product that part PEO content is high is used by FDA (FDA) approval.

In pharmaceutical carrier research and development, whether pharmaceutical carrier enter cell, enter the quantity of cell, enter cell after to act on what position be problem demanding prompt solution.

Summary of the invention

The object of the invention is to provide a kind of polymkeric substance, as pharmaceutical carrier, and can conveniently can see whether this pharmaceutical carrier enters cell, enters the quantity of cell.Additionally provide the preparation method of this polymkeric substance simultaneously.

Inventive polymers FA-P85-PLA concrete structure formula is as follows:

(specifically seeing Fig. 1).

Its synthetic route is as Fig. 3, and concrete preparation method is:

(1) according to weight ratio, first by 1.92-3.84g folic acid (folic acid, FA) with 0.72g 1,3-dicyclohexylcarbodiimide (DCC) joins in 100ml anhydrous dimethyl sulfoxide (DMSO), at room temperature stir 20-30 hour, again 40g, 8.7mmol PluronicP85 and 0.39g DMAP (DMAP) is added wherein, continue at room temperature to stir 24-48 hour.Dialyse 24 hours at 30 DEG C with DMSO afterwards, until clarification (molecular weight cut-off of dialysis tubing is 3500) in dialysis tubing.Then dialyse two days at 30 DEG C, until removing that DMSO is all dialysed with deionized water.Then vacuum drying oven inner drying is put into again after being spin-dried for by product, finally obtained FA-P85-OH;

(2) do macromole evocating agent with FA-P85-OH and stannous octoate is catalyzer, under the condition of anhydrous, anaerobic, cause cyclic monomers lactide (lactide, LA) and carry out ring-opening polymerization, finally obtain required multipolymer.Concrete synthetic method is: reaction flask by vacuumize the deoxygenation of-Tong argon gas dehumidifying after, FA-P85-OH, rac-Lactide and stannous octoate is added under argon gas condition, the amount of rac-Lactide is 50 – 100% of FA-P85-OH weight, the amount of stannous octoate is the 0.1-0.15% of rac-Lactide weight, reactant is heated to 140-160 DEG C, under stirring, reaction continues 7-9 hour; Dissolved by reactant methylene dichloride, then sink in methyl alcohol, adularescent material settles out, and filters; And then use methylene dichloride dissolve polymer, and sink in methyl alcohol, filter, dry, obtain FA-P85-PLA multipolymer;

(3) get FA-P85-PLA 30mg and TMRCA 1-3mg to be dissolved in dry toluene solution, and under argon shield 80 DEG C of reaction 5h.By product molecular weight cut-off be afterwards 3500 dialysis tubing within 5 days, will wherein get rid of by responseless TMRCA dialysis in dimethyl formamide (DMF), freeze-drying after removing DMF for 3 days of dialysing in deionized water is again preserved, and has obtained final product FA-P85-PLA-TMRCA.

Polymkeric substance provided by the invention has pharmaceutical carrier and deixis concurrently, effectively can find out whether this pharmaceutical carrier enters cell, enters the quantity of cell, has good prospect.In addition, pharmaceutical carrier of the present invention, has good biocompatibility.

Accompanying drawing explanation

Fig. 1 is the chemical structural formula of FA-P85-PLGA-TMRCA high molecular fluorescent probe of the present invention;

Fig. 2 is the fluoroscopic image of Inventive polymers FA-P85-PLGA-TMRCA in Proliferation of Human Ovarian Cell OVCAR-3;

Fig. 3 Inventive polymers synthetic route.

Embodiment

Embodiment 1

1, first by 1.67g, 3.78mmol folic acid FA and 0.72g 1,3-dicyclohexylcarbodiimide (DCC) joins in 100ml anhydrous dimethyl sulfoxide (DMSO), at room temperature stirs 24 hours, again by 40g, 8.7mmol Pluronic P85 (PEO ₂₆-PPO ₄₀-PEO ₂₆) add wherein with 0.39g DMAP (DMAP), continue at room temperature to stir 48 hours.Dialyse 24 hours at 30 DEG C with DMSO afterwards, until clarification (molecular weight cut-off of dialysis tubing is 3500) in dialysis tubing.Then dialyse two days at 30 DEG C, until DMSO is all dialysed with deionized water.Then vacuum drying oven inner drying is put into again after being spin-dried for by product, finally obtained FA-P85-OH.Gained multipolymer is weighed as 23.6g, and productive rate is 56.6%.

2, reaction flask by vacuumize the deoxygenation of-Tong argon gas dehumidifying after, under argon gas condition, add 3gFA-P85-OH, rac-Lactide 3g and stannous octoate 4mg, reactant be heated to 150 DEG C, under stirring, reaction continue 8 hours; Dissolved by reactant methylene dichloride, then sink in methyl alcohol, adularescent material settles out, and filters; And then use methylene dichloride dissolve polymer, and sink in methyl alcohol, filter, dry, finally obtain FA-P85-PLA multipolymer (carrier) 2.37g, productive rate is 39.5%.

Structural characterization ¹h NMR (400MHz, CDCl ₃, ppm): 1.1-1.2 (m, CH ₃ofPPO block in P85), 1.5-1.7 (m, CH ₃of PLA block), 3.3-3.7 (m, OCH ₂cH ₂of PEO block and OCH ₂cH of PPO block in P85), 5.1-5.3 (m, CH of PLA block).

The molecular weight of FA-P85-PLA multipolymer prepared and the segment content of PLA are calculated by the nuclear magnetic spectrogram of FA-P85-PLA, result is the molecular weight (Mn) of FA-P85-PLA is 11600, the content of PLA segment is 56.5wt%, and also namely the structural formula of phase emergencing copolymer is FA-PEO ₂₆-PPO ₄₀-PEO ₂₆-PLA ₉₁.

3, get FA-P85-PLA 30mg and tetramethylrhodamine-5-carboxyl nitrine (tetramethylrhodamine-5-carbonyl azide, TMRCA) 1.3mg to be dissolved in dry toluene solution, and under argon shield 80 DEG C of reaction 5h.By product molecular weight cut-off be afterwards 3500 dialysis tubing within 5 days, will wherein get rid of by responseless TMRCA dialysis in dimethyl formamide (DMF), freeze-drying after removing DMF for 3 days of dialysing in deionized water is again preserved, and has finally obtained FA-P85-PLA-TMRCA.

4, fluorescent microscope experiment: Proliferation of Human Ovarian Cell OVCAR-3 is seeded on 96 orifice plates, and cell density is 2 × 10 ⁴individual cells/ml ^-1, at CO ₂8h is cultivated in incubator.Then the FA-P85-PLA-TMRCA nanoparticle aqueous solution is added in cell and cultivate 24h.Then fluorescence microscope fluoroscopic image is used.Fig. 2 is the result of fluoroscopic image.From fluorescence intracellular in figure, TMRCA is successfully attached on FA-P85-PLA multipolymer.And FA-P85-PLA-TMRCA nanoparticle successfully enters in OCVAR cell.

Claims

1. a polymkeric substance, its molecular structural formula is as follows:

2. polymkeric substance as claimed in claim 1, its preparation method comprises the following steps:

(1) first by 1.92-3.84g folic acid (folic acid, FA) with 0.72g 1,3-dicyclohexylcarbodiimide (DCC) joins in 100ml anhydrous dimethyl sulfoxide (DMSO), at room temperature stir 20-30 hour, again by 40g, 8.7mmol Pluronic P85 and 0.39g4-Dimethylamino pyridine (DMAP) add wherein, continue at room temperature to stir 24-48 hour.Dialyse 24 hours at 30 DEG C with DMSO afterwards, until clarification (molecular weight cut-off of dialysis tubing is 3500) in dialysis tubing.Then dialyse two days at 30 DEG C, until removing that DMSO is all dialysed with deionized water; Then vacuum drying oven inner drying is put into again after being spin-dried for by product.

(2) reaction flask by vacuumize the deoxygenation of-Tong argon gas dehumidifying after, step (1) products therefrom FA-P85-OH, rac-Lactide and stannous octoate is added under argon gas condition, the amount of rac-Lactide is 50 – 100% of FA-P85-OH weight, the amount of stannous octoate is the 0.1-0.15% of rac-Lactide weight, reactant is heated to 140-160 DEG C, under stirring, reaction continues 7-9 hour; Dissolved by reactant methylene dichloride, then sink in methyl alcohol, adularescent material settles out, and filters; And then use methylene dichloride dissolve polymer, and sink in methyl alcohol, filter, dry.

(3) get step (2) products therefrom 30mg and TMRCA 1-3mg to be dissolved in dry toluene solution, and under argon shield 80 DEG C of reaction 5h.By product molecular weight cut-off be afterwards 3500 dialysis tubing within 5 days, will wherein get rid of by responseless TMRCA dialysis in dimethyl formamide (DMF), freeze-drying after removing DMF for 3 days of dialysing in deionized water is again preserved, and has finally obtained polymkeric substance FA-P85-PLA-TMRCA.

3. polymkeric substance according to claim 1 is preparing the application of indicator type pharmaceutical carrier.

4. application according to claim 3, is characterized in that described indicator type pharmaceutical carrier is the indicator type pharmaceutical carrier that pharmaceutical carrier can be indicated to enter intracellular locations and quantity.